Hironori Fujii, Masami Tsuchiya, Daichi Watanabe, Ryo Otsuka, Daisuke Hirate, Katsuyuki Takahashi, Makiko Go, Toshihiro Kudo, Kazuhiro Shimomura, Yosuke Ando, et al. The emerging emetogenicity of trifluridine/tipiracil (TAS-102) from patient self-reporting: a multicenter, prospective, observational study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2024. 32. 5. 291-291
Kaori Takahashi, Ryuji Uozumi, Toru Mukohara, Tetsu Hayashida, Midori Iwabe, Hirotoshi Iihara, Kanako Kusuhara-Mamishin, Yuko Kitagawa, Masami Tsuchiya, Mika Kitahora, et al. Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer. The oncologist. 2024
J. Herrstedt, R. Clark-Snow, C. H. Ruhlmann, A. Molassiotis, I. Olver, B. L. Rapoport, M. Aapro, K. Dennis, P. J. Hesketh, R. M. Navari, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024. 9. 2
Senri Yamamoto, Masami Tsuchiya, Hirotoshi Iihara, Yoh Hayasaki, Kyoko Hori, Yasuo Kumakura, Daichi Watanabe, Hideki Sakai, Satoshi Nakagawa, Akiko Kudoh, et al. Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002). Journal of Cancer. 2024. 15. 6. 1487-1497
Florian Scotté, Lee Schwartzberg, Hirotoshi Iihara, Matti Aapro, Richard Gralla, Paul J Hesketh, Karin Jordan, Ronald Chow, Jørn Herrstedt. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2023. 32. 1. 45-45
Doublet or triplet antiemetic prophylaxis for trastuzumab deruxtecan-induced nausea and vomiting: An open-label, randomized, multicenter, exploratory phase 2 trial
(San Antonio Breast Cancer Symposium 2023)
Scotté F, Zelek L, Giuliano C, Tilola SO, Bailey WL, Ruhlmann CH, Iihara H, Aapro M
(ESMO Asia Congress 2023 2023)
2022/04 - 現在 The Multinational Association of Supportive Care in Cancer (MASCC)/ European Society For Medical Oncology (ESMO) Antiemetic Guideline Update Committee member
2022/07 - 第68回 日本薬学会東海支部総会・大会 学生優秀演題賞 オキサリプラチン投与時のデキサメタゾンによる pH 調整が血管痛の VAS に与える影響
2022/06 - 日本がんサポーティブケア学会 優秀演題賞 Patient-reported outcomes with dexamethasone sparing in CDDP-based chemotherapy: A randomized, placebo-controlled, phase III study (SPARED trial)
2019/09 - ESMO Congress 2019 Best Poster A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
2019/06 - American Society of Clinical Oncology Best of ASCO A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin based chemotherapy
2009/04 - MD Anderson Cancer Center Japanese Medical Exchange Program 2009 (MDアンダーソンがんセンターへの留学研修プログラム)
全件表示
所属学会 (10件):
日本がん薬剤学会
, European Society for Medical Oncology
, Multinational Association of Supportive Care in Cancer
, 日本がんサポーティブケア学会
, 日本臨床薬理学会
, 日本癌治療学会
, 臨床腫瘍薬学会
, 日本薬学会
, 日本臨床腫瘍学会
, 日本医療薬学会